uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells

Journal of Cell Biology

Volumn 178, Issue 3, 2007, Pages 425-436

  Lester, Robin D ^a   Jo, Minji ^a   Montel, Valérie ^a   Takimoto, Shinako ^a   Gonias, Steven L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT CHLORIDE; COLLAGEN; GLYCOGEN SYNTHASE KINASE 3BETA; MATRIGEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAC1 PROTEIN; TRANSCRIPTION FACTOR SNAIL; UROKINASE RECEPTOR; VIMENTIN;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CELL HYPOXIA; CELL INVASION; CELL MIGRATION; CHORIOALLANTOIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; EXPERIMENTAL MODEL; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MESENCHYME; METASTASIS; NONHUMAN; NUCLEAR IMPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANOXIA; ANTIMUTAGENIC AGENTS; BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; COBALT; COLLAGEN; ENZYME ACTIVATION; EPITHELIUM; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; MESODERM; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OXYGEN; PROTO-ONCOGENE PROTEINS C-AKT; RAC1 GTP-BINDING PROTEIN; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

GASTROPODA;

EID: 34547610957     PISSN: 00219525     EISSN: 00219525     Source Type: Journal    
DOI: 10.1083/jcb.200701092     Document Type: Article

References (70)

1. Akakura, N., M. Kobayashi, I. Horiuchi, A. Suzuki, J. Wang, J. Chen, H. Niizeki, K. Kawamura, M. Hosokawa, and M. Asaka. 2001. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 61:6548-6554.
2. Alfano, D., I. Iaccarino, and M.P. Stoppelli. 2006. Urokinase signaling through tts receptor protects against anoikis by increasing BCL-xL expression levels. J. Biol. Chem. 281:17758-17767.
3. Anand-Apte, B., B.R. Zetter, A. Viswanathan, R.-G. Qiu, J. Chen, R. Ruggieri, and M. Symons. 1997. Platelet-derived growth factor and fibronectin-stimulated migration are differentially regulated by the Rac and extracellular signal-regulated kinase pathways. J. Biol. Chem. 272:30688-30692.
4. Andreasen, P.A., L. Kjøller, L. Christenson, and M.J. Duffy. 1997. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer. 72:1-22.
5. Arany, Z., L.E. Huang, R. Eckner, S. Bhattacharya, C. Jiang, M.A. Goldberg, H.F. Bunn, and D.M. Livingston. 1996. An essential role for p300/ CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA. 93:12969-12973.
6. Azim, A.C., K.L. Barkalow, and J.H. Hartwig. 2000. Determination of GTP loading on Rac and Cdc42 in platelets and fibroblasts. Methods Enzymol. 325:257-263.
7. Bachelder, R.E., S.-O. Yoon, C. Franci, A.G. de Herreros, and A.M. Mercurio. 2005. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J. Cell Biol. 168:29-33.
8. Bando, H., M. Toi, K. Kitada, and M. Koike. 2003. Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231. Biomed. Pharmacother. 57:333-340.
9. Batlle, E., E. Sancho, C. Franci, D. Dominguez, M. Monfar, J. Baulida, and A. Garcia De Herreros. 2000. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2:84-89.
10. Bianchi, E., R.L. Cohen, A.T. Thor, R.F. Todd III, I.F. Mizukami, D.A. Lawrence, B.M. Ljung, M.A. Shuman, and H.S. Smith. 1994. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res. 54:861-866.
11. Blasi, F., and P. Carmeliet. 2002. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3:932-943.
12. Cano, A., M.A. Perez-Moreno, I. Rodrigo, A. Locascio, M.J. Blanco, M.G. del Barrio, F. Portillo, and M.A. Nieto. 2000. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2:76-83.
13. Catling, A.D., H.J. Schaeffer, C.W. Reuter, G.R. Reddy, and M.J. Weber. 1995. A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function. Mol. Cell. Biol. 15:5214-5225.
14. Chandrasekar, N., S. Mohanam, M. Gujrati, W.C. Olivero, D.H. Dinh, and J.S. Rao. 2003. Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells. Oncogene. 22:392-400.
15. Cheng, J.Q., C.W. Lindsley, G.Z. Cheng, H. Yang, and S.V. Nicosia. 2005. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene. 24:7482-7492.
16. Chia, S.K., C.C. Wykoff, P.H. Watson, C. Han, R.D. Leek, J. Pastorek, K.C. Gatter, P. Ratcliffe, and A.L. Harris. 2001. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol. 19:3660-3668.
17. Cho, S.Y., and R.L. Klemke. 2002. Purification of pseudopodia from polarized cells reveals redistribution and activation of Rac through assembly of a CAS/Crk scaffold. J. Cell Biol. 156:725-736.
18. Conley, B.A., J.J. Wright, and S. Kummar. 2006. Targeting epigenetic abnormalities with histone deacetylase inhibitors. Cancer. 107:832-840.
19. Costello, J.F., and C. Plass. 2001. Methylation matters. J. Med. Genet. 38:285-303.
20. de Vries, T.J., P.H. Quax, M. Denijn, K.N. Verrijp, J.H. Verheijen, H.W. Verspaget, U.H. Weidle, D.J. Ruiter, and G.N. van Muijen. 1994. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am. J. Pathol. 144:70-81.
21. Del Vecchio, S., M.P. Stoppelli, M.V. Carriero, R. Fonti, O. Massa, P.Y. Li, G. Botti, M. Cerra, G. D'Aiuto, G. Esposito, et al. 1993. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res. 53:3198-3206.
22. Forsythe, J.A., B.H. Jiang, N.V. Iyer, F. Agani, S.W. Leung, R.D. Koos, and G.L. Semenza. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:4604-4613.
23. Graham, C.H., J. Forsdike, C.J. Fitzgerald, and S. Macdonald-Goodfellow. 1999. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int. J. Cancer. 80:617-623.
24. Grille, S.J., A. Bellacosa, J. Upson, A.J. Klein-Szanto, F. van Roy, W. Lee-Kwon, M. Donowitz, P.N. Tsichlis, and L. Larue. 2003. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 63:2172-2178.
25. Grunert, S., M. Jechlinger, and H. Beug. 2003. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol. 4:657-665.
26. Guhaniyogi, J., and G. Brewer. 2001. Regulation of mRNA stability in mammalian cells. Gene. 265:11-23.
27. Harris, A.L. 2002. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2:38-47.
28. Harrison, L., and K. Blackwell. 2004. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist. 9:31-40.
29. Hayman, E.G., M.D. Pierschbacher, Y. Ohgren, and E. Ruoslahti. 1983. Serum spreading factor (vitronectin) is present at the cell surface and in tissues. Proc. Natl. Acad. Sci. USA. 80:4003-4007.
30. Imai, T., A. Horiuchi, C. Wang, K. Oka, S. Ohira, T. Nikaido, and I. Konishi. 2003. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am. J. Pathol. 163:1437-1447.
31. Jo, M., K.S. Thomas, D.M. O'Donnell, and S.L. Gonias. 2003. Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J. Biol. Chem. 278:1642-1646.
32. Jo, M., K.S. Thomas, S. Takimoto, A. Gaultier, E.H. Hsieh, R.D. Lester, and S.L. Gonias. 2007. Urokinase receptor primes cells to proliferate in response to epidermal growth factor. Oncogene. 26:2585-2594.
33. Kim, J., W. Yu, K. Kovalski, and L. Ossowski. 1998. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell. 94:353-362.
34. Kiyan, J., R. Kiyan, H. Haller, and I. Dumler. 2005. Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-beta. EMBO J. 24:1787-1797.
35. Kjoller, L., and A. Hall. 2001. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J. Cell Biol. 152:1145-1157.
36. Krishnamachary, B., S. Berg-Dixon, B. Kelly, F. Agani, D. Feldser, G. Ferreira, N. Iyer, J. LaRusch, B. Pak, P. Taghavi, and G.L. Semenza. 2003. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 63:1138-1143.
37. Krishnamachary, B., D. Zagzag, H. Nagasawa, K. Rainey, H. Okuyama, J.H. Baek, and G.L. Semenza. 2006. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res. 66:2725-2731.
38. Larue, L., and A. Bellacosa. 2005. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 24:7443-7454.
39. Lester, R.D., M. Jo, W.M. Campana, and S.L. Gonias. 2005. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J. Biol. Chem. 280:39273-39277.
40. Leyland-Jones, B. 2003. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 4:459-460.
41. Liu, D., J.A.A. Ghiso, Y. Estrada, and L. Ossowski. 2002. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell. 1:445-457.
42. Ma, Z., D.J. Webb, M. Jo, and S.L. Gonias. 2001. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J. Cell Sci. 114:3387-3396.
43. Ma, Z., K.S. Thomas, D.J. Webb, R. Moravec, A.M. Salicioni, W.M. Mars, and S.L. Gonias. 2002. Regulation of Rac1 activation by the low density lipoprotein receptor-related protein. J. Cell Biol. 159:1061-1070.
44. Matos, P., and P. Jordan. 2006. Rac1, but not Rac1B, stimulates RelB-mediated gene transcription in colorectal cancer cells. J. Biol. Chem. 281:13724-13732.
45. Monaghan-Benson, E., and P.J. McKeown-Longo. 2006. Urokinase-type plasminogen activator receptor regulates a novel pathway of fibronectin matrix assembly requiring Src-dependent transactivation of epidermal growth factor receptor. J. Biol. Chem. 281:9450-9459.
46. Nguyen, D.H., I.M. Hussaini, and S.L. Gonias. 1998. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J. Biol. Chem. 273:8502-8507.
47. Nguyen, D.H., A.D. Catling, D.J. Webb, M. Sankovic, L.A. Walker, A.V. Somlyo, M.J. Weber, and S.L. Gonias. 1999. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J. Cell Biol. 146:149-164.
48. Nieto, M.A. 2002. The Snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. 3:155-166.
49. O'Reilly, M.S., L. Holmgren, C. Chen, and J. Folkman. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2:689-692.
50. Ossowski, L., and J.A. Aguirre-Ghiso. 2000. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 12:613-620.
51. Pennacchietti, S., P. Michieli, M. Galluzzo, M. Mazzone, S. Giordano, and P.M. Comoglio. 2003. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 3:347-361.
52. Radisky, D.C., D.D. Levy, L.E. Littlepage, H. Liu, C.M. Nelson, J.E. Fata, D. Leake, E.L. Godden, D.G. Albertson, M.A. Nieto, et al. 2005. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 436:123-127.
53. Resnati, M., I. Pallavicini, J.M. Wang, J. Oppenheim, C.N. Serhan, M. Romano, and F. Blasi. 2002. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. USA. 99:1359-1364.
54. Rofstad, E.K., H. Rasmussen, K. Galappathi, B. Mathiesen, K. Nilsen, and B.A. Graff. 2002. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res. 62:1847-1853.
55. Schuster, S.J., E.V. Badiavas, P. Costa-Giomi, R. Weinmann, A.J. Erslev, and J. Caro. 1989. Stimulation of erythropoietin gene transcription during hypoxia and cobalt exposure. Blood. 73:13-16.
56. Schvartz, I., D. Seger, and S. Shaltiel. 1999. Vitronectin. Int. J. Biochem. Cell Biol. 31:539-544.
57. Semenza, G.L. 2001. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol. Med. 7:345-350.
58. Semenza, G.L. 2004. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda). 19:176-182.
59. Singh, A., A.E. Karnoub, T.R. Palmby, E. Lengyel, J. Sondek, and C.J. Der. 2004. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene. 23:9369-9380.
60. Thiery, J.P. 2002. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer. 2:442-454.
61. Thompson, E.W., D.F. Newgreen, and D. Tarin. 2005. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res. 65:5991-5995.
62. Vaupel, P., and L. Harrison. 2004. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist. 9:4-9.
63. Vial, E., E. Sahai, and C.J. Marshall. 2003. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell. 4:67-79.
64. Wang, G.L., and G.L. Semenza. 1993. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Natl. Acad. Sci. USA. 90:4304-4308.
65. Wei, Y., M. Lukashev, D.I. Simon, S.C. Bodary, S. Rosenberg, M.V. Doyle, and H.A. Chapman. 1996. Regulation of integrin function by the urokinase receptor. Science. 273:1551-1555.
66. Wei, Y., J.A. Eble, Z. Wang, J.A. Kreidberg, and H.A. Chapman. 2001. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol. Biol. Cell. 12:2975-2986.
67. Wei, Y., C.-H. Tang, Y. Kim, L. Robillard, F. Zhang, M.C. Kugler, and H.A. Chapman. 2006. Urokinase receptors are required for alpha 5beta 1 integrin-mediated signaling in tumor cells. J. Biol. Chem. 282:3929-3939.
68. Zhang, F., C.C. Tom, M.C. Kugler, T.T. Ching, J.A. Kreidberg, Y. Wei, and H.A. Chapman. 2003. Distinct ligand binding sites in integrin alpha3beta1 regulate matrix adhesion and cell-cell contact. J. Cell Biol. 163:177-188.
69. Zhou, B.P., J. Deng, W. Xia, J. Xu, Y.M. Li, M. Gunduz, and M.-C. Hung. 2004. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 6:931-940.
70. Zhou, J., T. Schmid, S. Schnitzer, and B. Brune. 2006. Tumor hypoxia and cancer progression. Cancer Lett. 237:10-21.